nodes	percent_of_prediction	percent_of_DWPC	metapath
Pyrimethamine—DHFR—Methotrexate—multiple sclerosis	0.618	0.672	CbGbCtD
Pyrimethamine—CYP2D6—Fingolimod—multiple sclerosis	0.159	0.173	CbGbCtD
Pyrimethamine—CYP2C8—Dexamethasone—multiple sclerosis	0.0608	0.0661	CbGbCtD
Pyrimethamine—CYP2C9—Dexamethasone—multiple sclerosis	0.0424	0.0461	CbGbCtD
Pyrimethamine—CYP2D6—Dexamethasone—multiple sclerosis	0.0388	0.0422	CbGbCtD
Pyrimethamine—Anaemia megaloblastic—Azathioprine—multiple sclerosis	0.00849	0.18	CcSEcCtD
Pyrimethamine—DHFR—Nucleotide Metabolism—SRM—multiple sclerosis	0.00639	0.188	CbGpPWpGaD
Pyrimethamine—Anaemia megaloblastic—Methotrexate—multiple sclerosis	0.00342	0.0724	CcSEcCtD
Pyrimethamine—DHFR—Nucleotide Metabolism—RRM1—multiple sclerosis	0.00341	0.101	CbGpPWpGaD
Pyrimethamine—DHFR—Fluoropyrimidine Activity—RRM1—multiple sclerosis	0.00219	0.0647	CbGpPWpGaD
Pyrimethamine—Leukopenia—Fingolimod—multiple sclerosis	0.0017	0.0359	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Cladribine—multiple sclerosis	0.00161	0.034	CcSEcCtD
Pyrimethamine—Pancytopenia—Cladribine—multiple sclerosis	0.00147	0.031	CcSEcCtD
Pyrimethamine—Stevens-Johnson syndrome—Cladribine—multiple sclerosis	0.00137	0.0289	CcSEcCtD
Pyrimethamine—Toxic epidermal necrolysis—Azathioprine—multiple sclerosis	0.00131	0.0277	CcSEcCtD
Pyrimethamine—Pancytopenia—Azathioprine—multiple sclerosis	0.00119	0.0252	CcSEcCtD
Pyrimethamine—Erythema multiforme—Cladribine—multiple sclerosis	0.00117	0.0247	CcSEcCtD
Pyrimethamine—DHFR—E2F transcription factor network—RRM1—multiple sclerosis	0.00116	0.0343	CbGpPWpGaD
Pyrimethamine—Stevens-Johnson syndrome—Azathioprine—multiple sclerosis	0.00111	0.0235	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—RRM1—multiple sclerosis	0.00101	0.0298	CbGpPWpGaD
Pyrimethamine—Pancytopenia—Mitoxantrone—multiple sclerosis	0.000964	0.0204	CcSEcCtD
Pyrimethamine—Erythema multiforme—Azathioprine—multiple sclerosis	0.00095	0.0201	CcSEcCtD
Pyrimethamine—Haematuria—Mitoxantrone—multiple sclerosis	0.000863	0.0183	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Cladribine—multiple sclerosis	0.00086	0.0182	CcSEcCtD
Pyrimethamine—Anorexia—Cladribine—multiple sclerosis	0.000837	0.0177	CcSEcCtD
Pyrimethamine—Leukopenia—Azathioprine—multiple sclerosis	0.000783	0.0166	CcSEcCtD
Pyrimethamine—Decreased appetite—Cladribine—multiple sclerosis	0.000763	0.0162	CcSEcCtD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP24A1—multiple sclerosis	0.000711	0.021	CbGpPWpGaD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP27B1—multiple sclerosis	0.000711	0.021	CbGpPWpGaD
Pyrimethamine—Thrombocytopenia—Azathioprine—multiple sclerosis	0.000699	0.0148	CcSEcCtD
Pyrimethamine—Hypersensitivity—Cladribine—multiple sclerosis	0.000647	0.0137	CcSEcCtD
Pyrimethamine—Leukopenia—Mitoxantrone—multiple sclerosis	0.000633	0.0134	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Mitoxantrone—multiple sclerosis	0.000577	0.0122	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Mitoxantrone—multiple sclerosis	0.000565	0.012	CcSEcCtD
Pyrimethamine—Vomiting—Cladribine—multiple sclerosis	0.000558	0.0118	CcSEcCtD
Pyrimethamine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000554	0.0164	CbGpPWpGaD
Pyrimethamine—CYP2C8—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000554	0.0164	CbGpPWpGaD
Pyrimethamine—Anorexia—Mitoxantrone—multiple sclerosis	0.00055	0.0116	CcSEcCtD
Pyrimethamine—CYP2C8—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000547	0.0161	CbGpPWpGaD
Pyrimethamine—CYP2C8—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000547	0.0161	CbGpPWpGaD
Pyrimethamine—Toxic epidermal necrolysis—Methotrexate—multiple sclerosis	0.000527	0.0111	CcSEcCtD
Pyrimethamine—Hypersensitivity—Azathioprine—multiple sclerosis	0.000526	0.0111	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL4—multiple sclerosis	0.000514	0.0152	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Mitoxantrone—multiple sclerosis	0.000502	0.0106	CcSEcCtD
Pyrimethamine—Pancytopenia—Methotrexate—multiple sclerosis	0.00048	0.0102	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Prednisolone—multiple sclerosis	0.000474	0.01	CcSEcCtD
Pyrimethamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000455	0.0134	CbGpPWpGaD
Pyrimethamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000455	0.0134	CbGpPWpGaD
Pyrimethamine—Vomiting—Azathioprine—multiple sclerosis	0.000454	0.00961	CcSEcCtD
Pyrimethamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP24A1—multiple sclerosis	0.000451	0.0133	CbGpPWpGaD
Pyrimethamine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP27B1—multiple sclerosis	0.000451	0.0133	CbGpPWpGaD
Pyrimethamine—CYP2C8—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000449	0.0133	CbGpPWpGaD
Pyrimethamine—CYP2C8—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000449	0.0133	CbGpPWpGaD
Pyrimethamine—CYP2D6—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000449	0.0133	CbGpPWpGaD
Pyrimethamine—CYP2D6—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000449	0.0133	CbGpPWpGaD
Pyrimethamine—Stevens-Johnson syndrome—Methotrexate—multiple sclerosis	0.000447	0.00946	CcSEcCtD
Pyrimethamine—CYP2C9—Oxidation by Cytochrome P450—CYP27B1—multiple sclerosis	0.000445	0.0131	CbGpPWpGaD
Pyrimethamine—CYP2C9—Oxidation by Cytochrome P450—CYP24A1—multiple sclerosis	0.000445	0.0131	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Triamcinolone—multiple sclerosis	0.000435	0.00921	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Methylprednisolone—multiple sclerosis	0.000435	0.00919	CcSEcCtD
Pyrimethamine—Haematuria—Methotrexate—multiple sclerosis	0.00043	0.0091	CcSEcCtD
Pyrimethamine—Hypersensitivity—Mitoxantrone—multiple sclerosis	0.000425	0.009	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—ICAM1—multiple sclerosis	0.000409	0.0121	CbGpPWpGaD
Pyrimethamine—Anaphylactic shock—Dexamethasone—multiple sclerosis	0.000395	0.00836	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Betamethasone—multiple sclerosis	0.000395	0.00836	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Betamethasone—multiple sclerosis	0.000387	0.00819	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Dexamethasone—multiple sclerosis	0.000387	0.00819	CcSEcCtD
Pyrimethamine—Erythema multiforme—Methotrexate—multiple sclerosis	0.000383	0.0081	CcSEcCtD
Pyrimethamine—Anorexia—Betamethasone—multiple sclerosis	0.000377	0.00797	CcSEcCtD
Pyrimethamine—Anorexia—Dexamethasone—multiple sclerosis	0.000377	0.00797	CcSEcCtD
Pyrimethamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000369	0.0109	CbGpPWpGaD
Pyrimethamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000369	0.0109	CbGpPWpGaD
Pyrimethamine—Vomiting—Mitoxantrone—multiple sclerosis	0.000367	0.00777	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—CCL2—multiple sclerosis	0.000366	0.0108	CbGpPWpGaD
Pyrimethamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP27B1—multiple sclerosis	0.000366	0.0108	CbGpPWpGaD
Pyrimethamine—CYP2C9—Phase 1 - Functionalization of compounds—CYP24A1—multiple sclerosis	0.000366	0.0108	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Prednisolone—multiple sclerosis	0.000349	0.00738	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Prednisone—multiple sclerosis	0.000344	0.00728	CcSEcCtD
Pyrimethamine—Decreased appetite—Dexamethasone—multiple sclerosis	0.000343	0.00727	CcSEcCtD
Pyrimethamine—Decreased appetite—Betamethasone—multiple sclerosis	0.000343	0.00727	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—ALB—multiple sclerosis	0.000341	0.0101	CbGpPWpGaD
Pyrimethamine—Anorexia—Prednisone—multiple sclerosis	0.000328	0.00694	CcSEcCtD
Pyrimethamine—Hypersensitivity—Triamcinolone—multiple sclerosis	0.000321	0.00679	CcSEcCtD
Pyrimethamine—Hypersensitivity—Methylprednisolone—multiple sclerosis	0.00032	0.00677	CcSEcCtD
Pyrimethamine—Leukopenia—Methotrexate—multiple sclerosis	0.000315	0.00667	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IFNG—multiple sclerosis	0.000311	0.00918	CbGpPWpGaD
Pyrimethamine—Decreased appetite—Prednisone—multiple sclerosis	0.000299	0.00633	CcSEcCtD
Pyrimethamine—Anaphylactic shock—Methotrexate—multiple sclerosis	0.000288	0.00608	CcSEcCtD
Pyrimethamine—Thrombocytopenia—Methotrexate—multiple sclerosis	0.000282	0.00596	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL1B—multiple sclerosis	0.000277	0.00819	CbGpPWpGaD
Pyrimethamine—Vomiting—Triamcinolone—multiple sclerosis	0.000277	0.00586	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—IL2—multiple sclerosis	0.000276	0.00816	CbGpPWpGaD
Pyrimethamine—Vomiting—Methylprednisolone—multiple sclerosis	0.000276	0.00585	CcSEcCtD
Pyrimethamine—Anorexia—Methotrexate—multiple sclerosis	0.000274	0.0058	CcSEcCtD
Pyrimethamine—Hypersensitivity—Prednisone—multiple sclerosis	0.000254	0.00536	CcSEcCtD
Pyrimethamine—Vomiting—Betamethasone—multiple sclerosis	0.000251	0.00532	CcSEcCtD
Pyrimethamine—Vomiting—Dexamethasone—multiple sclerosis	0.000251	0.00532	CcSEcCtD
Pyrimethamine—Decreased appetite—Methotrexate—multiple sclerosis	0.00025	0.00529	CcSEcCtD
Pyrimethamine—CYP2C8—Biological oxidations—CYP24A1—multiple sclerosis	0.000239	0.00704	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—CYP27B1—multiple sclerosis	0.000239	0.00704	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000235	0.00695	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000235	0.00695	CbGpPWpGaD
Pyrimethamine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—multiple sclerosis	0.000232	0.00686	CbGpPWpGaD
Pyrimethamine—Vomiting—Prednisone—multiple sclerosis	0.000219	0.00463	CcSEcCtD
Pyrimethamine—CYP2D6—Melatonin metabolism and effects—APOE—multiple sclerosis	0.000213	0.00629	CbGpPWpGaD
Pyrimethamine—Hypersensitivity—Methotrexate—multiple sclerosis	0.000212	0.00448	CcSEcCtD
Pyrimethamine—DHFR—Folate Metabolism—TNF—multiple sclerosis	0.000201	0.00594	CbGpPWpGaD
Pyrimethamine—DHFR—E2F transcription factor network—MYC—multiple sclerosis	0.000199	0.00588	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—CYP24A1—multiple sclerosis	0.000196	0.00578	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—CYP27B1—multiple sclerosis	0.000196	0.00578	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—CYP27B1—multiple sclerosis	0.000194	0.00573	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—CYP24A1—multiple sclerosis	0.000194	0.00573	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000193	0.0057	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000193	0.0057	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—CYP27B1—multiple sclerosis	0.000192	0.00565	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metapathway biotransformation—CYP24A1—multiple sclerosis	0.000192	0.00565	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—SRM—multiple sclerosis	0.000187	0.00553	CbGpPWpGaD
Pyrimethamine—Vomiting—Methotrexate—multiple sclerosis	0.000183	0.00387	CcSEcCtD
Pyrimethamine—DHFR—Retinoblastoma (RB) in Cancer—MYC—multiple sclerosis	0.000173	0.00511	CbGpPWpGaD
Pyrimethamine—DHFR—Folate Metabolism—IL6—multiple sclerosis	0.000162	0.00479	CbGpPWpGaD
Pyrimethamine—DHFR—G1/S Transition—MYC—multiple sclerosis	0.000145	0.00427	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—GPC5—multiple sclerosis	0.000144	0.00426	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CYP24A1—multiple sclerosis	0.000132	0.0039	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—CYP27B1—multiple sclerosis	0.000132	0.0039	CbGpPWpGaD
Pyrimethamine—CYP2C8—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000125	0.00368	CbGpPWpGaD
Pyrimethamine—DHFR—Mitotic G1-G1/S phases—MYC—multiple sclerosis	0.000122	0.0036	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—GPC5—multiple sclerosis	0.000121	0.00356	CbGpPWpGaD
Pyrimethamine—CYP2D6—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000102	0.00302	CbGpPWpGaD
Pyrimethamine—CYP2C9—Cytochrome P450 - arranged by substrate type—POMC—multiple sclerosis	0.000101	0.00299	CbGpPWpGaD
Pyrimethamine—CYP2C8—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	0.000101	0.00298	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—RRM1—multiple sclerosis	0.0001	0.00295	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—RPL5—multiple sclerosis	9.38e-05	0.00277	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	9.16e-05	0.0027	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	9.16e-05	0.0027	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—SLC11A1—multiple sclerosis	8.98e-05	0.00265	CbGpPWpGaD
Pyrimethamine—CYP2D6—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.3e-05	0.00245	CbGpPWpGaD
Pyrimethamine—CYP2C9—Phase 1 - Functionalization of compounds—POMC—multiple sclerosis	8.23e-05	0.00243	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP27B1—multiple sclerosis	7.46e-05	0.0022	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—CYP24A1—multiple sclerosis	7.46e-05	0.0022	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CD28—multiple sclerosis	7.17e-05	0.00212	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—SRM—multiple sclerosis	5.79e-05	0.00171	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—BCHE—multiple sclerosis	5.75e-05	0.0017	CbGpPWpGaD
Pyrimethamine—CYP2C8—Biological oxidations—POMC—multiple sclerosis	5.37e-05	0.00158	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CD86—multiple sclerosis	5.12e-05	0.00151	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—SRM—multiple sclerosis	4.76e-05	0.0014	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—SRM—multiple sclerosis	4.71e-05	0.00139	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CCR5—multiple sclerosis	4.54e-05	0.00134	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MYC—multiple sclerosis	4.47e-05	0.00132	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—HLA-A—multiple sclerosis	4.42e-05	0.00131	CbGpPWpGaD
Pyrimethamine—CYP2D6—Biological oxidations—POMC—multiple sclerosis	4.41e-05	0.0013	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle, Mitotic—MAPK1—multiple sclerosis	4.37e-05	0.00129	CbGpPWpGaD
Pyrimethamine—CYP2C9—Biological oxidations—POMC—multiple sclerosis	4.37e-05	0.00129	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—APOE—multiple sclerosis	4.13e-05	0.00122	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYP24A1—multiple sclerosis	4.08e-05	0.0012	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—CYP27B1—multiple sclerosis	4.08e-05	0.0012	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MYC—multiple sclerosis	4e-05	0.00118	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.99e-05	0.00118	CbGpPWpGaD
Pyrimethamine—DHFR—Cell Cycle—MAPK1—multiple sclerosis	3.91e-05	0.00115	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CD80—multiple sclerosis	3.73e-05	0.0011	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—GPC5—multiple sclerosis	3.73e-05	0.0011	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—APOE—multiple sclerosis	3.46e-05	0.00102	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYP27B1—multiple sclerosis	3.35e-05	0.000989	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—CYP24A1—multiple sclerosis	3.35e-05	0.000989	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYP24A1—multiple sclerosis	3.32e-05	0.00098	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—CYP27B1—multiple sclerosis	3.32e-05	0.00098	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—BCHE—multiple sclerosis	3.25e-05	0.000958	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—TYK2—multiple sclerosis	3.15e-05	0.00093	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—RRM1—multiple sclerosis	3.09e-05	0.000913	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—GPC5—multiple sclerosis	3.06e-05	0.000904	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—GPC5—multiple sclerosis	3.04e-05	0.000897	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—POMC—multiple sclerosis	2.97e-05	0.000877	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—CD4—multiple sclerosis	2.85e-05	0.000841	CbGpPWpGaD
Pyrimethamine—DHFR—Metabolism—ALB—multiple sclerosis	2.71e-05	0.000799	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—RRM1—multiple sclerosis	2.54e-05	0.000749	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—RRM1—multiple sclerosis	2.52e-05	0.000743	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	2.4e-05	0.000708	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—STAT3—multiple sclerosis	2.21e-05	0.000651	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	2.06e-05	0.000608	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MYC—multiple sclerosis	2.05e-05	0.000605	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—TGFB1—multiple sclerosis	2.05e-05	0.000604	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—MAPK1—multiple sclerosis	2.01e-05	0.000592	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—APOE—multiple sclerosis	1.95e-05	0.000576	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.88e-05	0.000555	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—BCHE—multiple sclerosis	1.78e-05	0.000524	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—POMC—multiple sclerosis	1.68e-05	0.000495	CbGpPWpGaD
Pyrimethamine—DHFR—Disease—IL6—multiple sclerosis	1.54e-05	0.000455	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism of lipids and lipoproteins—ALB—multiple sclerosis	1.53e-05	0.000451	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—BCHE—multiple sclerosis	1.46e-05	0.00043	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—BCHE—multiple sclerosis	1.45e-05	0.000427	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—APOE—multiple sclerosis	1.07e-05	0.000315	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—POMC—multiple sclerosis	9.18e-06	0.000271	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—APOE—multiple sclerosis	8.77e-06	0.000259	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—APOE—multiple sclerosis	8.7e-06	0.000257	CbGpPWpGaD
Pyrimethamine—CYP2C8—Metabolism—ALB—multiple sclerosis	8.37e-06	0.000247	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—POMC—multiple sclerosis	7.54e-06	0.000222	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—POMC—multiple sclerosis	7.47e-06	0.000221	CbGpPWpGaD
Pyrimethamine—CYP2D6—Metabolism—ALB—multiple sclerosis	6.87e-06	0.000203	CbGpPWpGaD
Pyrimethamine—CYP2C9—Metabolism—ALB—multiple sclerosis	6.81e-06	0.000201	CbGpPWpGaD
